Delivery Order SPE2DB25D3020-SPE2DB25FWKPB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,425.95 to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This firm fixed-price delivery order, issued on August 18, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation and was competitively awarded. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,425.95 delivery order on August 13, 2025, for 270 tablets of Esbriet 267 mg, a pulmonary fibrosis medication. This competitively awarded, firm fixed-price contract contains no set-aside designation and is scheduled for completion by September 4, 2025. The pharmaceutical supply will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child...
- The Defense Logistics Agency awarded a $17,129.75 delivery order to AmerisourceBergen Drug Corp for 90 tablets of Esbriet 801 mg, a pharmaceutical treatment primarily used for idiopathic pulmonary fibrosis. This firm fixed-price delivery order, which was competitively awarded without set-aside provisions, is scheduled for completion by September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, leveraging the company's...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used to treat idiopathic pulmonary fibrosis. The contract, awarded on July 21, 2025, with an ultimate completion date of August 11, 2025, was competitively awarded without set-aside provisions. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Esbriet 801 mg tablets (90-count units) with a contract ceiling value of $3,425.95. This non-set-aside, competitively awarded delivery order carries firm fixed pricing and is scheduled for completion by June 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under...
- The Defense Logistics Agency awarded a $3,425.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This non-set-aside competitive award was issued on June 16, 2025, with an ultimate completion date of July 9, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract action...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,425.95 for 90 tablets of Esbriet 801 mg, with a completion date of June 24, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken. This delivery order falls under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical will be delivered to the company's corporate office location in...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Esbriet (pirfenidone) 801 mg tablets in a 90-count package. This competitively awarded, firm fixed price delivery order carries a ceiling value of $3,425.95 and is scheduled for completion by July 10, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,425.95 for 90 tablets of ESBRIET 801 MG, a pharmaceutical product used in the treatment of idiopathic pulmonary fibrosis. This competitively awarded, firm fixed-price delivery order was issued on August 18, 2025, with an ultimate completion date of September 9, 2025. The contract carries no set-aside designation, indicating it was competed among eligible vendors meeting federal procurement standards....
- SPE2DB25D3020Indefinite Delivery Contract
- SPE2DB25D3020-SPE2DB25FWKPBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 270 tablets of Esbriet 267 mg, a pharmaceutical product used primarily for pulmonary fibrosis treatment. This competitively awarded, firm fixed-price delivery order has a ceiling value of $6,851.90 and is scheduled for completion by October 3, 2025. The contract specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate headquarters. No set-aside designation was applied to this award. This delivery order is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and established critical vendor for federal medical procurement, AmerisourceBergen leverages this comprehensive IDC vehicle to supply an extensive portfolio of pharmaceuticals and medical supplies supporting military healthcare systems, the Defense Health Agency, and other government healthcare customers worldwide. The company's consistent receipt of competitively awarded delivery orders demonstrates its capability to fulfill federal medical supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.9k | 9/12/25 |